Compare ARK Genomic Revolution ETF (ARKG) vs Plby Group Inc (PLBY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Plby Group Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.21, while Plby Group Inc trades at $1.16 (market cap $134.09M). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | PLBY | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $43.57 | $2.71 |
52-Week Low | $23.09 | $1.14 |
Market Cap | — | $134.09M |
Enterprise Value | — | $281.90M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
PLBY trades at $1.16 with no recent price movement, showing technical bearish signals despite oversold RSI readings. The company has shown improving fundamentals with revenue stabilizing around $120-122 million and narrowing losses from -$278M in 2022 to -$13M in 2025. Recent positive developments include Russell index inclusion and a strategic share repurchase program. Operating cash flow turned positive in 2025 after years of negative performance, though the company maintains high debt levels with a debt-to-asset ratio of 59.52%.
While PLBY shows operational improvement and strong analyst support (75% buy ratings), significant risks remain including negative shareholder equity, high debt burden, and inconsistent earnings performance. The stock presents a turnaround opportunity if management can sustain EBITDA growth and debt reduction, but requires careful monitoring of cash flow sustainability and licensing revenue stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
